益佰制药：预计2025年净利润亏损2.85亿元-3.42亿元

Core Viewpoint - Yibai Pharmaceutical announced a profit warning for the fiscal year 2025, expecting a net loss attributable to shareholders of between 285 million to 342 million yuan, indicating a significant deterioration compared to a loss of 317.22 million yuan in the same period last year [1] Financial Performance - The company anticipates a decline in revenue due to reduced sales of its main products [1] - Although costs have decreased, they remain higher than revenue, contributing to the expected losses [1] - The company plans to recognize an impairment provision for goodwill between 110 million to 132 million yuan, which will further exacerbate the losses [1]